Business Wire

NY-PHILIP-MORRIS-INTL

Share
PMI’s Charles Bendotti Recognized by INvolve and Yahoo Finance on OUTstanding 50 Ally Executives List 2020; Nikki Symmons named on LGBT+ Future Leader List 2020

Charles Bendotti, Senior Vice President, People & Culture at Philip Morris International Inc. (PMI) (NYSE:PM), has today been recognized for his unwavering support for LGBTQ+ inclusion in the workplace, included on INvolve and Yahoo Finance’s OUTstanding 50 Ally Executives List 2020. The designation places Bendotti among a select group of business leaders and allies of LGBTQ+ inclusion recognized for driving cultural change within the workplace to create more inclusive environments across the world. Nikki Symmons, Content Planner, Global Communications at PMI, has also been named on the OUTstanding LGBT+ Future Leader List 2020 in recognition of her achievements in furthering LGBTQ+ inclusion both within PMI and beyond.

“I’ve been fortunate to have lived and led in many countries throughout my career, working with people from a variety of backgrounds and cultures who have taught me the value of inclusion and diversity first-hand,” said Bendotti. “I’m honored to be recognized as a global ally and included on the OUTstanding 50 Ally Executives List this year. As leaders it’s critical that everyone—without exception—feels valued, respected, and empowered to succeed.”

Bendotti’s recognition stems from his efforts in championing inclusion and diversity (I&D) within PMI and beyond. He was instrumental in championing the appointment of the company’s first Chief Diversity Officer, Silke Muenster, in March 2020; a role that reports directly to the CEO. Additionally, he is actively involved in advancing LGBTQ+ inclusion within the organization as executive sponsor of PMI’s global employee resource group, STRIPES, which aims to create a safe space for learning, sharing, allyship, and support to members and allies of the LGBTQ+ community.

Suki Sandhu OBE, founder, and CEO of INvolve, the consultancy and global network championing diversity and inclusion in business, said: “I’m thrilled to be celebrating another amazing group of LGBT+ and Ally role models from across the globe who are championing inclusion and inspiring the next generation of talent. LGBT+ discrimination is still prevalent across the world, and role models are essential to change perceptions and show everyone that you can be successful in business while also being your authentic self at work.”

For inclusion on the OUTstanding 50 Ally Executives List 2020, nominees’ seniority and influence were taken into consideration and their impact on LGBTQ+ inclusion inside and outside the workplace, as well as business achievements. They must be a vocal ally, actively working to create an environment where LGBTQ+ people can comfortably bring their best professional selves to work.

OUTstanding’s judging panel consisted of Lord Browne, executive chairman, L1 Energy; Ashok Vaswani, global consumer and payments head, Barclays; Harriet Green, former chairman and CEO, IBM Asia Pacific; Dawn Airey, independent director, Grosvenor Estates GBI; Jim Fitterling, CEO of Dow Inc.; Suki Sandhu OBE, founder and CEO, INvolve and Audeliss; and Lianna Brinded, head of Yahoo Finance UK.

The full list of nominees can be viewed here . For more information on PMI’s I&D efforts, click here .

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

About INvolve and OUTstanding

OUTstanding is part of INvolve, the consultancy and global network championing diversity and inclusion in business. Through the delivery of events, programs, thought leadership, and advisory services, INvolve helps firms drive cultural change and create inclusive workplaces where any individual can succeed. INvolve also publishes EMpower, HERoes, and OUTstanding role model lists annually, recognizing and celebrating business leaders and future leaders who are breaking down barriers at work and inspiring the next generation of diverse talent. For more information, please visit www.involvepeople.org

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye